Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 5/20 | 0.54 |
| ▸ | HTR2B | P41595 | 3/20 | 0.54 |
| ▸ | PRCP | P42785 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 1/20 | 0.51 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.51 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CCNK | O75909 | 1/20 | 0.47 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21206860 | 0.87 | HTR2C (0.70) | POLBHTR2CHTR2BGID4KDM4E | |
| SCHEMBL18257088 | 0.87 | HTR2C (0.55) | TAAR1HTR2CHTR2BPRCPGID4 | |
| Hydrochloric Acid SCHEMBL20489700 | 0.86 | HTR2C (0.68) | POLBHTR2CHTR2BGID4KDM4E | |
| SCHEMBL21540823 | 0.86 | HTR2C (0.60) | POLBHTR2CHTR2BPRCPKDM4E | |
| Hydrochloric Acid SCHEMBL20489702 | 0.86 | HTR2C (0.68) | POLBHTR2CHTR2BGID4KDM4E | |
| SCHEMBL2089397 | 0.86 | HTR2C (0.60) | TAAR1POLBHTR2CHTR2BPRCP | |
| SCHEMBL2089398 | 0.86 | HTR2C (0.60) | TAAR1POLBHTR2CHTR2BPRCP | |
| SCHEMBL2089855 | 0.86 | HTR2C (0.60) | TAAR1POLBHTR2CHTR2BPRCP | |
| SCHEMBL21540822 | 0.85 | HTR2C (0.57) | TAAR1HTR2CHTR2BPRCPGID4 | |
| Hydrochloric Acid SCHEMBL11095820 | 0.84 | HTR2C (0.59) | TAAR1POLBHTR2CHTR2BPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654834-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | GPR119, FFAR1, FFAR3 | TAAR1 121/4885POLB 4646/4885HTR2C 722/4885 |
| US-10654834-B2 | Non-systemic TGR5 agonists | GPR119, SSTR5, FFAR3 | TAAR1 132/4885POLB 4626/4885HTR2C 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.